Journal article
Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements
Lonnele J Ball, Nitzan Levy, Xiaoyue Zhao, Chandi Griffin, Mary Tagliaferri, Isaac Cohen, William A Ricke, Terence P Speed, Gary L Firestone, Dale C Leitman
MOLECULAR AND CELLULAR ENDOCRINOLOGY | ELSEVIER IRELAND LTD | Published : 2009
Abstract
Selective estrogen receptor modulators (SERMs), such as tamoxifen and raloxifene can act as estrogen receptor (ER) antagonists or agonists depending on the cell type. The antagonistic action of tamoxifen has been invaluable for treating breast cancer, whereas the agonist activity of SERMs also has important clinical applications as demonstrated by the use of raloxifene for osteoporosis. Whereas the mechanism whereby SERMs function as antagonists has been studied extensively very little is known about how SERMs produce agonist effects in different tissues with the two ER types; ERalpha and ERbeta. We examined the regulation of 32 SERM-responsive regions with ERalpha and ERbeta in transiently ..
View full abstractGrants
Awarded by NATIONAL CANCER INSTITUTE
Funding Acknowledgements
We thank Pierre Chambon and Jan-Ake Gustafsson for providing plasmids. We also thank Zhijin Wu and Yunxia Sui for providing us the dbRMA package for microarray analysis. This work was supported by a grant from the American Cancer Society to D.C.L.